|
1
|
Cohn SL, Pearson AD, London WB, Monclair
T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et
al: The International Neuroblastoma Risk Group (INRG)
Classification system: An INRG task force report. J Clin Oncol.
27:289–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Monclair T, Brodeur GM, Ambros PF, Brisse
HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK,
Nuchtern JG, et al: The International Neuroblastoma risk group
(INRG) staging system: An INRG task force report. J Clin Oncol.
27:298–303. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brodeur GM: Neuroblastoma: Biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tolbert VP and Matthay KK: Neuroblastoma:
Clinical and biological approach to risk stratification and
treatment. Cell Tissue Res. 372:195–209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mordant P, Loriot Y, Lahon B, Castier Y,
Leseche G, Soria JC, Massard C and Deutsch E: Minimal residual
disease in solid neoplasia: New frontier or red-herring? Cancer
Treat Rev. 38:101–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uemura S, Ishida T, Thwin KKM, Yamamoto N,
Tamura A, Kishimoto K, Hasegawa D, Kosaka Y, Nino N, Lin KS, et al:
Dynamics of minimal residual disease in neuroblastoma patients.
Front Oncol. 9:4552019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beiske K, Ambros PF, Burchill SA, Cheung
IY and Swerts K: Detecting minimal residual disease in
neuroblastoma patients-the present state of the art. Cancer Lett.
228:229–240. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brownhill SC and Burchill SA: PCR-based
amplification of circulating RNAs as prognostic and predictive
biomarkers-Focus on neuroblastoma. Pract Lab Med. 7:41–44. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stutterheim J, Zappeij-Kannegieter L,
Versteeg R, Caron HN, van der Schoot CE and Tytgat GA: The
prognostic value of fast molecular response of marrow disease in
patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer.
47:1193–1202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Viprey VF, Gregory WM, Corrias MV,
Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R,
Valteau-Couanet D, et al: Neuroblastoma mRNAs predict outcome in
children with stage 4 neuroblastoma: A European HR-NBL1/SIOPEN
study. J Clin Oncol. 32:1074–1083. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheung NK, Ostrovnaya I, Kuk D and Cheung
IY: Bone marrow minimal residual disease was an early response
marker and a consistent independent predictor of survival after
anti-GD2 immunotherapy. J Clin Oncol. 33:755–763. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marachelian A, Villablanca JG, Liu CW, Liu
B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R,
et al: Expression of five neuroblastoma genes in bone marrow or
blood of patients with relapsed/refractory neuroblastoma provides a
new biomarker for disease and prognosis. Clin Cancer Res.
23:5374–5383. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thwin KKM, Ishida T, Uemura S, Yamamoto N,
Lin KS, Tamura A, Kozaki A, Saito A, Kishimoto K, Mori T, et al:
Level of seven neuroblastoma-associated mRNAs detected by droplet
digital PCR is associated with tumor relapse/regrowth of high-risk
neuroblastoma patients. J Mol Diagn. 22:236–246. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park JR, Bagatell R, Cohn SL, Pearson AD,
Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K,
Nuchtern JG, et al: Revisions to the International Neuroblastoma
Response Criteria: A consensus statement from the National cancer
institute clinical trials planning meeting. J Clin Oncol.
35:2580–2587. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huggett JF, Foy CA, Benes V, Emslie K,
Garson JA, Haynes R, Hellemans J, Kubista M, Mueller RD, Nolan T,
et al: The digital MIQE guidelines: Minimum information for
publication of quantitative digital PCR experiments. Clin Chem.
59:892–902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaneko M, Tsuchida Y, Mugishima H, Ohnuma
N, Yamamoto K, Kawa K, Iwafuchi M, Sawada T and Suita S:
Intensified chemotherapy increases the survival rates in patients
with stage 4 neuroblastoma with MYCN amplification. J Pediatr
Hematol Oncol. 24:613–621. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Donfrancesco A, Jenkner A, Castellano A,
Ilari I, Milano GM, De Sio L, Cozza R, Fidani P, Deb G, De
Laurentis C, et al: Ifosfamide/carboplatin/etoposide (ICE) as
front-line, topotecan/cyclophosphamide as second-line and oral
temozolomide as third-line treatment for advanced neuroblastoma
over one year of age. Acta Paediatr Suppl. 93:6–11. 2007.
View Article : Google Scholar
|
|
20
|
Coustan-Smith E, Sancho J, Hancock ML,
Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH
and Campana D: Use of peripheral blood instead of bone marrow to
monitor residual disease in children with acute lymphoblastic
leukemia. Blood. 100:2399–2402. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kitamura K, Nishiyama T, Ishiyama K,
Miyawaki S, Miyazaki K, Suzuki K, Masaie H, Okada M, Ogawa H, Imai
K, et al: Clinical usefulness of WT1 mRNA expression in bone marrow
detected by a new WT1 mRNA assay kit for monitoring acute myeloid
leukemia: A comparison with expression of WT1 mRNA in peripheral
blood. Int J Hematol. 103:53–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang Q, Zhao XY, Qin YZ, Liu YR, Lai YY,
Jiang B and Huang XJ: The differences and correlations of BCR-ABL
transcripts between peripheral blood and bone marrow assays are
associated with the molecular responses in the bone marrow for
chronic myelogenous leukemia. Am J Hematol. 87:1065–1069. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moss TJ and Sanders DG: Detection of
neuroblastoma cells in blood. J Clin Oncol. 8:736–740. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seeger RC, Reynolds CP, Gallego R, Stram
DO, Gerbing RB and Matthay KK: Quantitative tumor cell content of
bone marrow and blood as a predictor of outcome in stage IV
neuroblastoma: A Children's Cancer Group Study. J Clin Oncol.
18:4067–4076. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yanez Y, Hervas D, Grau E, Oltra S, Perez
G, Palanca S, Bermudez M, Marquez C, Canete A and Castel V: TH and
DCX mRNAs in peripheral blood and bone marrow predict outcome in
metastatic neuroblastoma patients. J Cancer Res Clin Oncol.
142:573–580. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin KS, Uemura S, Thwin KKM, Nakatani N,
Ishida T, Yamamoto N, Tamura A, Saito A, Mori T, Hasegawa D, et al:
Minimal residual disease in high-risk neuroblastoma shows a dynamic
and disease burden-dependent correlation between bone marrow and
peripheral blood. Transl Oncol. 14:1010192021. View Article : Google Scholar : PubMed/NCBI
|
